RAPT Therapeutics Changes Fiscal Year End

Rapt Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyRapt Therapeutics, Inc.
Form Type8-K
Filed DateJun 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: fiscal-year-change, administrative

TL;DR

RAPT Therapeutics is shifting its fiscal year end from Dec 31 to June 30, effective this year.

AI Summary

On June 13, 2025, RAPT Therapeutics, Inc. filed an 8-K report indicating a change in its fiscal year end from December 31 to June 30. This change will be effective for the fiscal year ending June 30, 2025. The company, previously known as FLX Bio, Inc., is headquartered in South San Francisco, California.

Why It Matters

This change in fiscal year end may impact reporting schedules and financial comparisons for investors and analysts. It could also signal internal operational adjustments or strategic alignment with specific industry cycles.

Risk Assessment

Risk Level: low — The filing is a routine administrative change regarding the company's fiscal year end and does not involve significant financial transactions or operational shifts.

Key Numbers

  • 1231 — Previous Fiscal Year End (The company previously ended its fiscal year on December 31.)
  • 0630 — New Fiscal Year End (The company is changing its fiscal year end to June 30.)

Key Players & Entities

  • RAPT Therapeutics, Inc. (company) — Registrant
  • FLX Bio, Inc. (company) — Former company name
  • June 13, 2025 (date) — Date of earliest event reported
  • June 30, 2025 (date) — New fiscal year end
  • December 31 (date) — Previous fiscal year end
  • South San Francisco, California (location) — Principal Executive Offices

FAQ

What is the new fiscal year end for RAPT Therapeutics, Inc.?

The new fiscal year end for RAPT Therapeutics, Inc. is June 30, effective for the fiscal year ending June 30, 2025.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on June 13, 2025.

What was RAPT Therapeutics, Inc. formerly known as?

RAPT Therapeutics, Inc. was formerly known as FLX Bio, Inc.

Where are RAPT Therapeutics, Inc.'s principal executive offices located?

RAPT Therapeutics, Inc.'s principal executive offices are located at 561 Eccles Avenue, South San Francisco, California.

What is the primary reason for this 8-K filing?

This 8-K filing is to report an amendment to the company's articles of incorporation or bylaws regarding a change in its fiscal year.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding RAPT Therapeutics, Inc..

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.